Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 22, 2024 (Event Date)
Reporting Period: The filing addresses a delinquency regarding the Form 10-Q for the period ended March 31, 2024.
Key Financial Metrics
This filing is a notice of regulatory non-compliance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
- Nasdaq Delisting Notice: The Company received a notice from The Nasdaq Stock Market LLC on May 22, 2024, stating it is not in compliance with Listing Rule 5250(c)(1) due to the failure to timely file its Form 10-Q for the quarter ended March 31, 2024.
- Trading Status: The notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market.
- Compliance Timeline: The Company has 60 calendar days to submit a plan of compliance. Nasdaq may grant up to 180 calendar days from the Form 10-Q due date (November 11, 2024) to regain compliance.
- Reason for Delay: The delay in filing the Form 10-Q is attributed to an ongoing restatement analysis, as previously disclosed in a Form 8-K filed on May 24, 2024.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to take necessary steps to regain compliance with Nasdaq listing rules as soon as practicable. Management states that all parties are working diligently to complete the restatement analysis and file the overdue Form 10-Q.
Risks and Contingencies: The primary risk is potential delisting from the Nasdaq Capital Market if the Company fails to submit a compliance plan within 60 days or fails to regain compliance by the extended deadline of November 11, 2024. The ongoing restatement analysis represents a significant contingency affecting financial reporting.
Investor Verification Checklist
- Verify the status of the ongoing restatement analysis and its impact on historical financial data.
- Monitor the submission of the Company's compliance plan to Nasdaq within the 60-day window.
- Confirm the expected filing date for the delayed Form 10-Q for the period ended March 31, 2024.
- Review the May 24, 2024 Form 8-K referenced in this filing for details on the specific matters causing the restatement.